JP2002506818A5 - - Google Patents

Download PDF

Info

Publication number
JP2002506818A5
JP2002506818A5 JP2000536378A JP2000536378A JP2002506818A5 JP 2002506818 A5 JP2002506818 A5 JP 2002506818A5 JP 2000536378 A JP2000536378 A JP 2000536378A JP 2000536378 A JP2000536378 A JP 2000536378A JP 2002506818 A5 JP2002506818 A5 JP 2002506818A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
statin
acceptable salt
mmp inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000536378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002506818A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/024681 external-priority patent/WO1999047138A1/en
Publication of JP2002506818A publication Critical patent/JP2002506818A/ja
Publication of JP2002506818A5 publication Critical patent/JP2002506818A5/ja
Pending legal-status Critical Current

Links

JP2000536378A 1998-03-17 1998-11-20 スタチン−マトリックスメタロプロテイナーゼ阻害剤組み合わせ物 Pending JP2002506818A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17
US60/078,265 1998-03-17
PCT/US1998/024681 WO1999047138A1 (en) 1998-03-17 1998-11-20 Statin-matrix metalloproteinase inhibitor combinations

Publications (2)

Publication Number Publication Date
JP2002506818A JP2002506818A (ja) 2002-03-05
JP2002506818A5 true JP2002506818A5 (cg-RX-API-DMAC7.html) 2006-01-19

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000536378A Pending JP2002506818A (ja) 1998-03-17 1998-11-20 スタチン−マトリックスメタロプロテイナーゼ阻害剤組み合わせ物

Country Status (18)

Country Link
EP (1) EP1063991A1 (cg-RX-API-DMAC7.html)
JP (1) JP2002506818A (cg-RX-API-DMAC7.html)
KR (1) KR20010041916A (cg-RX-API-DMAC7.html)
AR (1) AR018113A1 (cg-RX-API-DMAC7.html)
AU (1) AU1591699A (cg-RX-API-DMAC7.html)
BR (1) BR9815745A (cg-RX-API-DMAC7.html)
CA (1) CA2309588A1 (cg-RX-API-DMAC7.html)
CO (1) CO5070670A1 (cg-RX-API-DMAC7.html)
GT (1) GT199900039A (cg-RX-API-DMAC7.html)
HN (1) HN1999000029A (cg-RX-API-DMAC7.html)
MY (1) MY140504A (cg-RX-API-DMAC7.html)
NZ (1) NZ505994A (cg-RX-API-DMAC7.html)
PA (1) PA8469001A1 (cg-RX-API-DMAC7.html)
PE (1) PE20000348A1 (cg-RX-API-DMAC7.html)
SV (1) SV1999000026A (cg-RX-API-DMAC7.html)
UY (1) UY25436A1 (cg-RX-API-DMAC7.html)
WO (1) WO1999047138A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA992106B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
US7816347B2 (en) 2004-12-15 2010-10-19 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ127198A3 (cs) * 1995-11-02 1998-12-16 Warner-Lambert Company Způsob regulace koncentrace lipidů a farmaceutická kompozice pro tento způsob
CZ294063B6 (cs) * 1996-05-17 2004-09-15 Warner-Lambert Company Bifenylsulfonamid, jeho použití a farmaceutický prostředek s jeho obsahem
MXPA99001974A (es) * 1996-12-09 2002-03-27 Warner Lambert Co Metodo para tratar y prevenir fallas cardiacas y dilatacion ventricular.
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.

Similar Documents

Publication Publication Date Title
JP2002501887A5 (ja) アルツハイマー病の治療用の薬剤の製造のための血漿トリグリセライドレベル低下剤の使用
JP2022116083A5 (cg-RX-API-DMAC7.html)
RU2333199C2 (ru) Производные дифенилазетидинона, способы их получения, содержащие их фармацевтические композиции и комбинация и их применение для ингибирования всасывания холестерина
RU2379295C2 (ru) Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона
HRP20241674T1 (hr) 6'-[[(1s,3s)-3-[[5-(difluormetoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i postupci njegove upotrebe
RU2005108133A (ru) Дипептиднитрильные ингибиторы катепсина к
JP2002508320A5 (cg-RX-API-DMAC7.html)
JP2004516285A5 (cg-RX-API-DMAC7.html)
JP2010509379A5 (cg-RX-API-DMAC7.html)
JP2007512347A5 (cg-RX-API-DMAC7.html)
JP2018504438A5 (cg-RX-API-DMAC7.html)
JP2012107018A (ja) S−[2−([[1−(2−エチルブチル)シクロヘキシル]カルボニル]アミノ)フェニル]2−メチルプロパンチオエートおよびHMG−CoA還元酵素阻害剤を含む併用
WO2001068096A2 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
TNSN04168A1 (fr) Derives de thiazole et d'oxazole qui modulent l'activite de ppar
RU99103623A (ru) Противотромбоцитная и антиатерогенная фармацевтическая композиция, содержащая тиенпиридиновое производное и ингибитор hmg-kоa-редуктазы
JP2008521827A5 (cg-RX-API-DMAC7.html)
JP2004521894A5 (cg-RX-API-DMAC7.html)
AR081032A1 (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
KR960703856A (ko) 축합 고리를 갖는 카르복실산 화합물, 이의 염 및 이의 약학적 용도(novel fused-ring carboxylic acid compound or salt thereof, and medicinal use thereof)
RU2351329C2 (ru) Ингибиторы кинуренин 3-гидроксилазы для лечения диабета
JP2007530528A5 (cg-RX-API-DMAC7.html)
RU2203661C2 (ru) Новые серосодержащие производные с амидной связью, способ их получения, их применение в качестве медикаментов и фармацевтические композиции
JP2003524582A5 (cg-RX-API-DMAC7.html)
PE20000348A1 (es) Composicion farmaceutica que comprende un inhibidor de metaloproteasa de matriz (mmp) y una estatina
JP2007536240A5 (cg-RX-API-DMAC7.html)